Randomised, Multicentric, Phase II Study of the Immunogenicity of a "Prime Boost" Vaccination Strategy Combining Conjugated Anti-Pneumococcal Vaccine (s0) and Polysaccharide Anti-Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency.

Trial Profile

Randomised, Multicentric, Phase II Study of the Immunogenicity of a "Prime Boost" Vaccination Strategy Combining Conjugated Anti-Pneumococcal Vaccine (s0) and Polysaccharide Anti-Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2016

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 23 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Jul 2012 New source identified and integrated (European Clinical Trials database record EudraCT2007-003235-23).
    • 16 Apr 2012 Planned End Date changed from 1 Dec 2011 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top